<DOC>
	<DOCNO>NCT00085878</DOCNO>
	<brief_summary>This phase I , open-label , dose-escalation study SB-485232 . Subjects receive SB-485232 administer subcutaneous injection daily 14 day . Dose escalation ( enrollment next cohort ) occur three subject complete previous cohort ; 5 dos test . An additional dosing regimen add evaluate higher dose give twice weekly 7 week . Therefore , full evaluation period patient extend approximately eleven week first day SB-485232 dosing .</brief_summary>
	<brief_title>Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically cytologically confirm diagnosis malignancy . Subjects solid tumor must locally advance metastatic disease time enrollment . Measurable evaluable disease refractory resistant standard therapy effective standard therapy . Predicted life expectancy least 12 week . Kinesin spindle protein ( KPS ) great 70 % . No chemotherapy , immunotherapy , hormonal therapy , biological therapy cancer , radiotherapy , surgical procedure ( except minor surgical procedure ) within 4 week begin treatment SB485232 ( 6 week nitrosoureas mitomycin C ) . Subjects must recover toxicity ( incur result previous therapy ) sufficiently enter Phase I study . Provide write informed consent . Absence antiSB485232 antibody . Hemoglobin great equal 9 g/dL . Absolute neutrophil count great equal 1.5 X 109 /L . Platelet count great equal 100 X 109 /L . Partial thromboplastin time ( PTT ) prothrombin time/international normalize ratio ( PT/INR ) within normal limit . Serum creatinine less equal 1.5 mg/dL ( 135 Âµmol/L ) estimate creatinine clearance great 50 mL/min ( calculate CockcroftGault Formula ) . Total serum bilirubin less equal 1.5 mg/dL . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) less equal 3 X ULN . Sexually active male female reproductive capacity must use adequate contraception . For subject history coronary artery disease , stress test must within normal limit . Subjects history congestive heart failure , myocardial infarction prior anthracycline chemotherapy must Multiple Gated Acquisition ( MUGA ) scan leave ventricular ejection fraction great 40 % . Women pregnant breastfeeding . Severe uncontrolled infection require systemic antibiotic therapy . Any serious medical psychiatric disorder would interfere subject safety inform consent . Known leptomeningeal disease evidence prior current metastatic brain disease . Receiving concurrent chemotherapy , immunotherapy , radiotherapy , investigational therapy . Receiving concurrent systemic steroid . History ventricular arrhythmia require drug device therapy . Any severe concurrent disease condition , include significant autoimmune disease , judgment principal investigator , would make subject inappropriate study participation . Any unresolved unstable serious toxicity prior administration another investigational drug . Any investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose SB485232 . Psychological , familial , sociological , geographical condition permit compliance study . Received prior treatment SB485232 . Poor venous access .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>IL-18</keyword>
	<keyword>subcutaneous</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Phase 1</keyword>
</DOC>